Trial Profile
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms KEEPsAKE 1
- Sponsors AbbVie; AbbVie Germany
- 15 Nov 2023 Results assessing efficacy and safety results through week 148, presented at the ACR Convergence 2023.
- 13 Jun 2023 This trial has been completed in Slovenia, according to European Clinical Trials Database record.
- 03 Jun 2023 Results of post-hoc analysis of two studies KEEPsAKE 1 and 2 assessing improvements in patient-reported outcomes, presented at the 24th Annual Congress of the European League Against Rheumatism.